EMEA monitoring EU radiopharm shortage
The European Medicines Agency (EMEA) has issued a statement on the current shortage of radiopharmaceuticals in the European Union. The main trigger for the problem has been the temporary closure of the nuclear reactor at Petten, the Netherlands, which the EMEA states is one of the key European production sites of radionuclide. This has been compounded by the planned shutdown of several other production facilities in EU member states.
Radiopharmaceuticals are drugs that either contain a radionuclide or are radiolabeled with one before its use. These are used in the diagnosis and treatment of a wide range of diseases. The EMEA added that the most commonly-used product of this type is molybdenum (99Mo)/technetium (99mTc).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze